Revenue from operations for the Q3 FY25 was reported at Rs 146.55 crore

Lincoln Pharmaceuticals has reported a standalone net profit of Rs 20.77 crore for the Q3 FY25 ended December 2024 as against a net profit of Rs 28.04 crore in the corresponding period last year. Revenue from operations for the Q3 FY25 was reported at Rs 146.55 crore over the previous fiscal’s same period revenue from operations of Rs 146.45 crore.

The company reported EBITDA of Rs. 32.63 crore in Q3 FY25 as compared to Rs 40.68 crore EBITDA in the corresponding period last year. EPS for Q3FY25 was at Rs. 10.37 per share.

The company reported a profit before tax of Rs 92.94 crores for the nine months ended December 2024 (9M FY25) to Rs 100.03 crores in 9M FY24. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company, rising from 3.22 per cent in December 2023 to 5.16 per cent in December 2024. With a clear growth strategy, the company is targeting revenue of Rs. 750 crores by FY26, driven by business expansion into high-value product lines and entry into new markets.

Notably, the company is among the select few to achieve consistent profit growth every year from FY13 to FY24.

Mahendra Patel, MD, Lincoln Pharmaceuticals, said, “We are pleased to report strong growth across all business verticals in the first nine months of FY25, with a vision to achieve record revenue, EBITDA, and net profit for the full year. The company aims to maintain steady growth while maintaining a net debt-free status. Our new product launches in domestic and export markets have boosted growth and market presence. Driven by strategic initiatives, operational excellence, and geographic expansion, we are on track to achieve Rs 750 crore revenue target by FY26. Notably, we are among the few companies with consistent profit growth from FY13 to FY24.”

For the nine months ended December 2024, the company reported a standalone revenue from operations of Rs 455.05 crore over the previous fiscal’s same period revenue from operations of Rs 438.06 crore. Net profit of the company was reported at Rs 70.77 crore for the nine months ended December 2024 as against net profit of Rs 74.71 crore in the corresponding period last year. EBITDA for the 9M FY25 ended December 2024 was reported at Rs 104.13 crore as compared to EBITDA of Rs 108.93 crore in 9M FY24. EPS for the nine months of FY25 was reported at Rs 35.33 per share. Exports (FOB) in nine months of FY25 were reported at Rs 271.83 crore.